Use your antibodies-online credentials, if available.
抗Human BRAF 抗体:
抗Rat (Rattus) BRAF 抗体:
抗Mouse (Murine) BRAF 抗体:
Human Polyclonal BRAF Primary Antibody for FACS, WB - ABIN1881118
Hingorani, Jacobetz, Robertson, Herlyn, Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. in Cancer research 2003
Show all 6 Pubmed References
Human Monoclonal BRAF Primary Antibody for IHC, ELISA - ABIN1724658
Rapp, Goldsborough, Mark, Bonner, Groffen, Reynolds, Stephenson: Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. in Proceedings of the National Academy of Sciences of the United States of America 1983
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody for IHC, ELISA - ABIN965693
Kim, Giuliano, Turner, Gaffney, Umetani, Kitago, Elashoff, Hoon: Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. in Annals of surgery 2006
Show all 5 Pubmed References
Human Monoclonal BRAF Primary Antibody for ICC, IHC - ABIN968991
Di Nicolantonio, Martini, Molinari, Sartore-Bianchi, Arena, Saletti, De Dosso, Mazzucchelli, Frattini, Siena, Bardelli: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008
Show all 2 Pubmed References
Human Monoclonal BRAF Primary Antibody for PLA, ELISA - ABIN513800
Liu, Chen, Chau, Jan, Chen, Hsu, Lin, Juang, Lu, Cheng, Chen, Chang, Ting, Kao, Hsiao, Huang: Analysis of protein-protein interactions in cross-talk pathways reveals CRKL protein as a novel prognostic marker in hepatocellular carcinoma. in Molecular & cellular proteomics : MCP 2013
Human Polyclonal BRAF Primary Antibody for ELISA, IHC (p) - ABIN5573331
Wiggans, Reilly, Kass, Maggs: Histologic and immunohistochemical predictors of clinical behavior for feline diffuse iris melanoma. in Veterinary ophthalmology 2016
Human Polyclonal BRAF Primary Antibody for DB - ABIN389897
Frattini, Ferrario, Bressan, Balestra, De Cecco, Mondellini, Bongarzone, Collini, Gariboldi, Pilotti, Pierotti, Greco: Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. in Oncogene 2004
Show all 3 Pubmed References
the present study identifies the WIPF1 (显示 WIPF1 抗体) gene as having novel oncogenic functions and playing an important role in the invasiveness and aggressiveness of thyroid cancer when aberrantly up-regulated by the BRAF V600E/MAPK (显示 MAPK1 抗体) pathway through its promoter demethylation.
BRAF mutation is associated with colonic neuroendocrine carcinoma.
c-Myc (显示 MYC 抗体), a downstream key effector of BRAF(V600E) signaling, was required for BRAF(V600E)-induced changes in lysine27-trimethylated histone H3 (显示 HIST3H3 抗体) through regulating the components of the polycomb (显示 CBX2 抗体) repressive complex 2 (PRC2) genes Ezh2 (显示 EZH2 抗体), Suz12 and Jarid2 (显示 JARID2 抗体) at both transcriptional levels via direct binding to their regulatory elements and post-transcriptional levels via repressing the miR (显示 MLXIP 抗体)-26a, miR (显示 MLXIP 抗体)-200b and miR (显示 MLXIP 抗体)-155.
Data show that depletion of SRY (sex determining region Y)-box 10 (显示 SOX10 抗体) protein (SOX10 (显示 SOX10 抗体)) sensitizes mutant proto-oncogene (显示 RAB1A 抗体) proteins B-raf (BRAF) melanoma cells to RAF (显示 RAF1 抗体) inhibitors in vitro and in vivo.
A panRAF inhibitor, LY3009120, potently inhibited proliferation and tumor growth in BRAF/KRAS mutated colorectal tumors.
In the coBRIM phase III trial, the addition of cobimetinib, an MEK (显示 MAP2K1 抗体) inhibitor, to vemurafenib, a BRAF inhibitor, significantly improved progression-free survival [hazard ratio (HR), 0.58; P < 0.0001] and overall survival (HR, 0.70; P = 0.005) in advanced BRAF-mutated melanoma. Here, we report on the incidence, course, and management of key adverse events (AEs (显示 AES 抗体)) in the coBRIM study
Report heterogeneity and frequency of BRAF mutations in primary melanoma samples.
Using a panel of BRAF V600E and WT colorectal cancer cell lines and in vitro selected resistant culture, and xenograft models, authors demonstrate here that BRAFV600E confers resistance to mTOR (显示 FRAP1 抗体) inhibitors.
Our model is trained to mimic the predictions of a 64-gene signature, the current definition of BRAF-positive group.
pediatric papillary thyroid carcinomas in Japan are characterized by more advanced clinicopathological features, lower BRAF (V600E) frequency, and absence of TERT (显示 TERT 抗体) mutation
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Xenopus, but exon 8b is present only in eutherians.
Gene expression studies nominated TWIST2 (显示 TWIST2 抗体) as a key effector downstream of BRAF.
BRAF alternative splicing is differentially regulated in vertebrates. Exon 9b is present in all vertebrates, including Danio rerio, but exon 8b is present only in eutherians.
BRAF activation is sufficient for f-nevus formation, and is among the primary events in melanoma development.
BRAF alternative splicing is differentially regulated in rodent and primates. Exon 9b is present in vertebrates but exon 8b is present only in eutherians.
mosaic expression of BRAF(V600E) in mouse erythro-myeloid progenitors results in clonal expansion of tissue-resident macrophages and a severe late-onset neurodegenerative disorder
CDX2 (显示 CDX2 抗体)(Null)/BRAF(V600E) expression in adult mouse intestinal epithelium led to serrated morphology tumors (including carcinomas) and BRAF(V600E) potently interacted with CDX2 (显示 CDX2 抗体) silencing to alter gene expression. Like human serrated lesions, CDX2 (显示 CDX2 抗体)(Null)/BRAF(V600E)-mutant epithelium expressed gastric markers.
expression of an endogenous Braf(D631A) kinase-inactive isoform in mice (corresponding to the human BRAF(D594A) mutation) triggers lung adenocarcinoma in vivo, indicating that BRAF-inactivating mutations are initiating events in lung oncogenesis
TTM (显示 SLITRK1 抗体) reduces copper levels and MAPK (显示 MAPK1 抗体) signaling, thereby inhibiting BRAF(V600E)-driven melanoma tumor growth.
BRAF and ROKalpha (显示 ROCK2 抗体) form independent RAF1 (显示 RAF1 抗体) complexes in embryonic fibroblasts (MEFs) treated with epidermal growth factor (EGF (显示 EGF 抗体)).
Braf(V600E) expression, coupled with simultaneous p53 (显示 TP53 抗体) ablation, permits bypass of senescence and progression to lung adenocarcinoma.
These results provide support for the role of BRAF(V600E) in metastasis.
Mechanistically, BRAF and RAF1 (显示 RAF1 抗体) operate independently to balance MAPK (显示 MAPK1 抗体) signaling: BRAF promotes ERK (显示 EPHB2 抗体) activation, while RAF1 (显示 RAF1 抗体) dims stress kinase activation.
Mass spectrometry based screening for potential interaction partners revealed that BRAF interacts and phosphorylates PAX3 (显示 PAX3 抗体).
Using a conditional allele for Braf(V600E) , a mutation observed in clinical cases of GIST, authors observed that Braf(V600E) activation was sufficient to drive ICC hyperplasia but not GIST tumorigenesis.
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene.
94 kDa B-raf protein
, B-Raf proto-oncogene serine/threonine-protein kinase (p94)
, murine sarcoma viral (v-raf) oncogene homolog B1
, proto-oncogene B-Raf
, serine/threonine-protein kinase B-raf
, v-raf murine sarcoma viral oncogene homolog B1
, B-Raf proto-oncogene serine/threonine-protein kinase
, proto-oncogene c-Rmil
, rmil serine/threonine-protein kinase
, serine/threonine kinase
, serine/threonine-protein kinase Rmil
, serine/threonine protein kinase BRAF
, serine/threonine-protein kinase B-raf-like
, B-raf protein